Adamis Pharmaceuticals Corp (ADMP)

[Rollgard1]

For new investors.


Tutes added including David Einhorn's Greenlight Capital.
• Tempol (MBM-02) for covid-19 treatment
• Tempol gel for skin cancer (IND)
• Zimhi (naloxone) for opioid overdose
• Symjepi (epinephrine) for allergic reaction
• Treatment for respiratory disease
• Treatment for inflammatory disease
• FDA: Zimhi NDA accepted for review
• FDA: Zimhi PDUFA target date 11/12/21
• CDC: 69K/yr opioid overdose deaths
• NIH: Tempol as potent covid antiviral
• Stanford: Tempol suppressed cytokines
• Tempol phase 2/3 trial starts 8/25/21
• Formed DSMB for phase 2/3
• Delta variant now dominant in US
•
$13M
from stock warrants
•
$5M
/USWM upon Zimhi FDA approval
• +
$21M
/USWM if Zimhi milestones met
• Sold part of USC subsidiary for
$15M

• Symjepi licensed to US WorldMeds
• Symjepi offered by Walgreens
• Symjepi sales increased 90%
• HHS to invest
$3B
in covid antiviral
• Vanguard 11.9 shares in all
• BlackRock 2.7M shares
• Greenlight 1M shares
• About
$40M
in cash (estimated)


Nice.....Thanks Roll........